Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 355 4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

Nakom Mar. 21 at 8:56 PM

$PULM I think 🤔 we will see over 3 this week. Its all good. 👍

0 · Reply

HomeRunHitterXXXXX Mar. 21 at 2:09 PM

$PULM hmmmmmmm 🧐

1 · Reply

BosFreedom Mar. 20 at 8:36 PM

$PULM what’s the deal with this stock? Why is it up?

0 · Reply

TRISTANX17 Mar. 20 at 5:40 PM

$PULM

0 · Reply

Nakom Mar. 20 at 5:35 PM

$PULM They will walk the stock back on low volume right now but I bet you there are few sellers.

0 · Reply

topstockalerts Mar. 20 at 5:27 PM

$PULM can get those sharp biotech spikes when attention hits. Not something that grinds slowly.

0 · Reply

ReversalTrack Mar. 20 at 5:17 PM

Something is brewing on ticker JAGU 🚨🚀 One of the most explosive signals is setting up on the daily. Uranium+Rare earth play with news . War changes everything especially energy. ⚛️ Uranium = energy independence + national security Don't sleep on ticker JAGU!! $SEDG $AIRG $PTN $PULM nice looks /1

0 · Reply

hiTHit Mar. 20 at 5:01 PM

$PULM If you had another option, would you want to hold this one?

1 · Reply

Nakom Mar. 20 at 4:14 PM

$PULM I bet you anything that UTHR and MNKD realize that Isperse is better than technosphere and there is a lot of work being done in the background right now. This price right now is rediculous. Someone will pay dearly for a DPI product. Just sit back and watch the Monet come rolling in.

1 · Reply

TheFinalBet Mar. 20 at 3:39 PM

$PULM

0 · Reply

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Feb 26, 2026, 8:05 AM EST - 23 days ago

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Dec 18, 2025, 8:05 AM EST - 3 months ago

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Oct 16, 2025, 8:05 AM EDT - 5 months ago

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Aug 6, 2025, 8:05 AM EDT - 8 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

May 15, 2025, 8:05 AM EDT - 11 months ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 9, 2025, 4:00 PM EDT - 11 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

GRDX

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 15, 2024, 9:35 AM EDT - 2 years ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 3 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

May 24, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 2, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 4 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

May 12, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 12:45 PM EDT - 4 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 4 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Nov 10, 2021, 4:15 PM EST - 4 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 9, 2021, 9:00 AM EST - 4 years ago

Pulmatrix Announces Resolution of Contract Dispute with Cipla

Nakom Mar. 21 at 8:56 PM

$PULM I think 🤔 we will see over 3 this week. Its all good. 👍

0 · Reply

HomeRunHitterXXXXX Mar. 21 at 2:09 PM

$PULM hmmmmmmm 🧐

1 · Reply

BosFreedom Mar. 20 at 8:36 PM

$PULM what’s the deal with this stock? Why is it up?

0 · Reply

TRISTANX17 Mar. 20 at 5:40 PM

$PULM

0 · Reply

Nakom Mar. 20 at 5:35 PM

$PULM They will walk the stock back on low volume right now but I bet you there are few sellers.

0 · Reply

topstockalerts Mar. 20 at 5:27 PM

$PULM can get those sharp biotech spikes when attention hits. Not something that grinds slowly.

0 · Reply

ReversalTrack Mar. 20 at 5:17 PM

0 · Reply

hiTHit Mar. 20 at 5:01 PM

$PULM If you had another option, would you want to hold this one?

1 · Reply

Nakom Mar. 20 at 4:14 PM

1 · Reply

TheFinalBet Mar. 20 at 3:39 PM

$PULM

0 · Reply

tilli5285 Mar. 20 at 2:51 PM

$PULM nice volume to start the morning. Especially on another red market day

0 · Reply

Nakom Mar. 20 at 2:38 AM

$PULM Well triple witching tomorrow shouldn’t really effect this stock tomorrow but a merger Monday announcement sure would. 🙏

0 · Reply

HomeRunHitterXXXXX Mar. 20 at 12:04 AM

$PULM ISPERSE is being used the clown is clueless saying it’s out of date 😂 130 patents or so

0 · Reply

HomeRunHitterXXXXX Mar. 20 at 12:03 AM

$PULM the board idiot is back

0 · Reply

madan_shatri Mar. 19 at 7:24 PM

$PULM Accept the fact that iSPERSE is out dated already. Don't beat about the bush. Only leverage this company offers to the industry is, it is listed with NASDAQ and its trading. How long can it continue to pay annual fee to keep it listed with NASDAQ can be a matter of debate now

1 · Reply

Nakom Mar. 19 at 7:20 PM

$PULM These swings are crazy for this stock. Wonder why somome waist there time shorting it for a few cents

0 · Reply

MinnieSteve3 Mar. 19 at 3:10 PM

$PULM Let's go, Mr. Ludlum. Sell the company/assets.

0 · Reply

Nakom Mar. 19 at 2:37 PM

$PULM Thanks for the 50 shares today at $2.02.

0 · Reply

Nakom Mar. 18 at 4:12 PM

$PULM Just picked up 50 shares for $2.13. Couldn’t resist.

0 · Reply

HomeRunHitterXXXXX Mar. 18 at 2:55 PM

$PULM why is this company letting Mannkind use ISPERSE for nothing they should of sold it to them just like they should of sold fend. This bs can’t be right imo.

1 · Reply

Nakom Mar. 17 at 6:22 PM

$PULM Anybody notice how there are very few shares for sale but lots of demand. Crazy.

0 · Reply

Nakom Mar. 17 at 1:40 PM

$PULM Let’s see if we can drop today. If it hits $2 I’m a buyer!!!

0 · Reply

Market Cap	9.09M
Revenue (ttm)	0.00
Net Income (ttm)	-5.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	83,000
Avg Vol	30,554
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	100%
Beta	1.68
Analysts	Strong Buy
Price Target	$10.00